Screener
Crinetics Pharmaceuticals CRNX EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Total other income, net | 12,533 | 14,631 |
| Net loss | (127,845) | (96,774) |
| Net loss per share: | ||
| Net loss per share — basic and diluted | $(1.23) | $(1.04) |
| Weighted average shares — basic and diluted | 104,099 | 93,102 |
| Other comprehensive income (loss): | ||
| Unrealized gain (loss) on investment securities | $(3,147) | $1,033 |
| Unrealized gain on foreign currency | 28 | 6 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's EPS (basic)?
- Crinetics Pharmaceuticals (CRNX) reported EPS (basic) of -$1.23 in Q1 2026.
- How has Crinetics Pharmaceuticals's EPS (basic) changed year-over-year?
- Crinetics Pharmaceuticals's EPS (basic) decreased by 18.3% year-over-year, from -$1.04 to -$1.23.
- What is the long-term trend for Crinetics Pharmaceuticals's EPS (basic)?
- Over 4 years (2021 to 2025), Crinetics Pharmaceuticals's EPS (basic) has grown at a 15.3% compound annual growth rate (CAGR), from -$2.80 to -$4.94.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.
Ask your AI about Crinetics Pharmaceuticals's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude